PO.MCB05.02 · 分子与细胞生物学
PARP1选择性抑制剂AZD5305在同源重组(HR)缺陷型胃癌细胞中表现出抗肿瘤作用并激发免疫反应
AZD5305, a PARP1 selective inhibitor, exhibits antitumor effects and stimulates immune response in homologous recombination (HR)-deficient gastric cancer cells
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:聚(ADP-核糖)聚合酶(PARP)1是一种多功能蛋白,因其在HR介导的DNA修复中的关键作用而广受认可,因此其抑制已被引入多种实体瘤的治疗。除DNA损伤反应(DDR)外,PARP1还作为免疫调节的关键调控因子而受到关注。这归因于胞质核酸(NAs)(如dsDNA或dsRNA)的积累,这些核酸被cGAS-STING等固有免疫通路所感知。然而,PARP1抑制诱导这些胞质核酸并激活固有免疫反应的确切机制仍有待阐明。因此,我们在胃癌细胞中研究了AZD5305的抗肿瘤和免疫调节作用,以探索其潜在机制。
方法:为评估体外抗肿瘤作用,以递增浓度的AZD5305(剂量范围:0-5nM)进行了为期14天的集落形成实验(CFA)。使用SNU-601异种移植模型通过监测肿瘤生长评估体内抗肿瘤活性。通过流式细胞术分析细胞周期分布,通过annexin-V/PI染色评估凋亡。通过彗星实验和细胞免疫荧光实验(IFA)检测DNA损伤。为研究免疫调节,通过qRT-PCR和Western blot定量免疫相关分子的表达,同时通过细胞IFA检测dsRNA的形成。使用细胞系进行RNAseq,以进行差异表达基因和基因集富集分析。
结果:RAD51C缺陷型SNU-601细胞对AZD5305高度敏感(IC50:0.25 nM),不同于中度敏感的SNU-668(IC50:2.05 nM)或耐药的KATOIII细胞(IC50>5 nM)。此外,AZD5305在SNU-601异种移植模型中表现出强效抗肿瘤活性(TGI 52.4%,p=0.003)。治疗后,SNU-601细胞表现出G2/M期阻滞和凋亡,经sub-G1群体增加、annexin-V染色阳性以及PARP和caspase-7的剪切所证实,而KATOIII中未出现。这种细胞毒性由DNA损伤积累驱动,表现为p-RPA、gammaH2AX升高及彗星尾形成。此外,AZD5305增加了SNU-601中的胞质dsRNA和cGAS-STING信号,触发固有免疫反应。与此一致,RNAseq证实SNU-601中激活的IFN-gamma反应通路富集,以及干扰素刺激基因(ISGs)表达相应升高,而KATOIII中未出现。
结论:AZD5305在体外和体内对HR缺陷型胃癌细胞系表现出强效细胞毒作用,通过诱导DNA损伤和凋亡性细胞死亡实现。AZD5305的免疫调节表现为伴随干扰素信号增强的固有免疫激活,我们的研究结果提示胞质dsRNA的形成是这一效应的关键介导者。
查看英文原文 English abstract
Background : Poly (ADP-ribose) polymerase (PARP) 1, a multifunctional protein, is widely recognized for its critical role in the HR-mediated DNA repair, and its inhibition has therefore been introduced into the treatment of various solid tumors. Besides DNA damage response (DDR), PARP1 has also emerged as a key regulator of immune modulation. This is attributed to the accumulation of cytosolic nucleic acids (NAs), such as dsDNA or dsRNA, which are sensed by innate immune pathways like cGAS-STING. However, the precise mechanisms by which PARP1 inhibition induces these cytosolic NAs and activates innate immune response remain to be elucidated. Thus, we investigated the anti-tumor and immune modulatory effects of AZD5305 in gastric cancer cells to explore the underlying mechanism.
Methods : To evaluate the in vitro antitumor effect, colony formation assay (CFA) was performed for 14 days with increasing concentrations of AZD5305 (dose range: 0-5nM). The in vivo antitumor activity was assessed using an SNU-601 xenograft model by monitoring tumor growth. Cell cycle distribution was analyzed by flow cytometry and apoptosis was assessed by annexin-V/PI staining. DNA damage was detected by comet assay and the cell immunofluorescence assay (IFA). To investigate immune modulation, the expression of immune-related molecules was quantified by qRT-PCR and western blot, while the formation of dsRNA was detected by cell IFA. RNAseq was performed using the cell lines for differentially expressed gene and gene set enrichment analyses.
Results : The RAD51C-deficient SNU-601 cells were highly sensitive to AZD5305 (IC 50 : 0.25 nM), unlike the moderately sensitive SNU-668 (IC 50 : 2.05 nM) or resistant KATOIII cells (IC 50 >5 nM). Moreover, AZD5305 demonstrated potent antitumor activity in an SNU-601 xenograft model (52.4% TGI, p =0.003). After treatment, SNU-601 cells exhibited G2/M arrest and apoptosis, confirmed by an increased sub-G1 population, positive annexin-V staining, and cleavage of PARP and caspase-7, but not in KATOIII. This cytotoxicity was driven by the accumulation of DNA damage, as indicated by elevated p-RPA, gammaH2AX, and comet tail formation. Furthermore, AZD5305 increased cytosolic dsRNA and cGAS-STING signaling in SNU-601, triggering the innate immune response. Consistent with this, RNAseq confirmed enrichments of activated IFN-gamma response pathways and corresponding increases in the expression of interferon-stimulated genes (ISGs) in SNU-601, but not in KATOIII.
Conclusion : AZD5305 exhibits potent cytotoxic effects in HR-deficient gastric cancer cell lines in vitro and in vivo , by inducing DNA damage and apoptotic cell death. Immune modulation by AZD5305 was characterized by innate immune activation with increased interferon signaling, and our findings suggest the formation of cytosolic dsRNA as a key mediator of this effect.
利益披露 Disclosure
S. Ham,
AstraZeneca ).
H. Hwang, None..
Y. Noh, None.
J. Koh,
AstraZeneca Other, Consulting fees.
C. Lee, None..
S. Lim, None..
M. Jeong, None..
Y. Kim, None..
M. Lee, None..
C. Park, None..
D. Lee, None.
K. Lee,
Roche ).
AstraZeneca Other, reported honoraria.
Eisai Other, reported honoraria.
Lilly Other, reported honoraria.
Novartis Other, reported honoraria.
Roche Other, reported honoraria.
Pfizer Other, reported honoraria.
S. Im,
AstraZeneca ), Other, Consulting fees.
Daiichi Sankyo ), Other, Consulting fees.
Eisai ), Other, Consulting fees.
Daewoong Pharm ).
Pfizer ), Other, Consulting fees.
Roche ), Other, Consulting fees.
Boryung Pharm ).
Hanmi Other, Consulting fees.
Lilly Other, Consulting fees.
MSD Other, Consulting fees.
Idience Other, Consulting fees.
Novartis Other, Consulting fees.
GSK Other, Consulting fees.